Stocks · News reference
Reported Saturday, 4D Molecular Therapeutics' 4D-150 Achieves 78% Overall Treatment Burden Reduction At 2 Years, With 87% Reduction In Recently Diagnosed Wet Age-Related Macular Degeneration Subgroup
After a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with consistent and durable treatment burden reduction through 2 years 4D-150 continues to be well tolerated with no new
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 20, 2026, 6:54 AM
- Checked
- Jul 20, 2026, 6:54 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
B. Riley Securities Initiates Coverage On 4D Molecular Therapeutics with Buy Rating, Announces Price Target of $37
B. Riley Securities analyst Mayank Mamtani initiates coverage on 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy rating and announces Price Target of $37.
Read original at benzinga4D Molecular's One-Shot Eye Therapy Delivers Two-Year Win
4D Molecular Therapeutics reports positive 2-year Phase 2b data for 4D-150 in wet AMD, showing up to an 87% cut in treatment burden.
Read original at benzinga8-K filing — 4D Molecular Therapeutics, Inc. (FDMT)
Filed: 2026-07-20 AccNo: 0001193125-26-308409 Size: 149 KB Item 8.01: Other Events
Read original at edgar